These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24864011)

  • 1. Potential candidate camelid antibodies for the treatment of protein-misfolding diseases.
    David MA; Jones DR; Tayebi M
    J Neuroimmunol; 2014 Jul; 272(1-2):76-85. PubMed ID: 24864011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PrP-specific camel antibodies with the ability to immunodetect intracellular prion protein.
    Tayebi M; Taylor WA; Jones DR; Bate C; David M
    J Gen Virol; 2010 Aug; 91(Pt 8):2121-2131. PubMed ID: 20375226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.
    Jones DR; Taylor WA; Bate C; David M; Tayebi M
    PLoS One; 2010 Mar; 5(3):e9804. PubMed ID: 20339552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.
    Ma QL; Lim GP; Harris-White ME; Yang F; Ambegaokar SS; Ubeda OJ; Glabe CG; Teter B; Frautschy SA; Cole GM
    J Neurosci Res; 2006 Feb; 83(3):374-84. PubMed ID: 16385556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro neutralization of prions with PrP(Sc)-specific antibodies.
    Taschuk R; Van der Merwe J; Marciniuk K; Potter A; Cashman N; Griebel P; Napper S
    Prion; 2015; 9(4):292-303. PubMed ID: 26284508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PrP antibodies detected at terminal stage of prion-affected mouse.
    Sassa Y; Kataoka N; Inoshima Y; Ishiguro N
    Cell Immunol; 2010; 263(2):212-8. PubMed ID: 20417929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the cellular prion protein on amyloid-β and 3PO-tau processing.
    Schmitz M; Wulf K; Signore SC; Schulz-Schaeffer WJ; Kermer P; Bähr M; Wouters FS; Zafar S; Zerr I
    J Alzheimers Dis; 2014; 38(3):551-65. PubMed ID: 24028865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.
    Enari M; Flechsig E; Weissmann C
    Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9295-9. PubMed ID: 11470893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion-like features of misfolded Aβ and tau aggregates.
    Morales R; Callegari K; Soto C
    Virus Res; 2015 Sep; 207():106-12. PubMed ID: 25575736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with either prion protein fragment 95-123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice.
    Bobkova NV; Medvinskaya NI; Kamynina AV; Aleksandrova IY; Nesterova IV; Samokhin AN; Koroev DO; Filatova MP; Nekrasov PV; Abramov AY; Leonov SV; Volpina OM
    Neurobiol Learn Mem; 2014 Jan; 107():50-64. PubMed ID: 24239620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers.
    Tayebi M; Jones DR; Taylor WA; Stileman BF; Chapman C; Zhao D; David M
    PLoS One; 2011; 6(5):e19998. PubMed ID: 21625515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates.
    Pan T; Chang B; Wong P; Li C; Li R; Kang SC; Robinson JD; Thompsett AR; Tein P; Yin S; Barnard G; McConnell I; Brown DR; Wisniewski T; Sy MS
    J Virol; 2005 Oct; 79(19):12355-64. PubMed ID: 16160162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
    Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
    J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
    Kanemaru K
    Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-α reduces beta-amyloid accumulation primarily by lowering cellular prion protein levels in a brain endothelial cell line.
    Yasutaka Y; Watanabe T; Nakashima A; Matsumoto J; Futagami K; Yamauchi A; Kataoka Y
    FEBS Lett; 2015 Jan; 589(2):263-8. PubMed ID: 25497018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between age, cerebral small vessel disease, parenchymal amyloid-β, and tau pathology: longitudinal studies in hypertensive stroke-prone rats.
    Schreiber S; Drukarch B; Garz C; Niklass S; Stanaszek L; Kropf S; Bueche C; Held F; Vielhaber S; Attems J; Reymann KG; Heinze HJ; Carare RO; Wilhelmus MM
    J Alzheimers Dis; 2014; 42 Suppl 3():S205-15. PubMed ID: 24825568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect.
    Liu YH; Bu XL; Liang CR; Wang YR; Zhang T; Jiao SS; Zeng F; Yao XQ; Zhou HD; Deng J; Wang YJ
    J Neuroinflammation; 2015 Aug; 12():153. PubMed ID: 26311039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.